Imbio PHA (4.0.0) vs KardiaAI
AI Verdict
Choose Imbio PHA (4.0.0) if…
Choose Imbio PHA (4.0.0) if your clinical practice requires automated, rapid analysis of CT pulmonary angiogram (CTPA) scans to assess right ventricular dilation and aid in the diagnosis and risk stratification of pulmonary embolism or hypertension. This tool is ideal for radiologists and cardiologists seeking precise, AI-powered measurements of cardiac structures directly from imaging data to inform critical care decisions.
View Imbio PHA (4.0.0) →Choose KardiaAI if…
Choose KardiaAI if you need an FDA-cleared AI software library for analyzing ambulatory ECG rhythms to detect various cardiac conditions such as AFib, bradycardia, or tachycardia. This tool is best suited for integration into mobile health applications or other ECG devices, providing continuous or on-demand heart rhythm analysis for patient monitoring and early detection of arrhythmias.
View KardiaAI →Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Quick Comparison
| Feature | Imbio PHA (4.0.0) | KardiaAI |
|---|---|---|
| Pricing | Unknown | Subscription-based for advanced features and services. |
| Deployment | Cloud (AWS) or On-premise (VMware) or via partners (Nuance, Aidoc, Siemens Syngo.via, TeraRecon, FerrumHealth, Flywheel). | Mobile app, cloud-based. |
| BAA Available | Unknown | Yes AI-estimated |
| FDA Status | Yes AI-estimated | Cleared AI-estimated |
| HIPAA | Yes AI-estimated | Yes AI-estimated |
Head-to-Head
AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.
Usability
Imbio PHA (4.0.0)Imbio PHA is designed for seamless integration into existing radiology DICOM workflows, generating annotated images and PDF reports that fit directly into a clinician's established routine. While KardiaAI offers an API for integration into mobile and web platforms, its direct end-user experience depends on the integrating application, potentially introducing variability. Imbio's focus on integrating with native DICOM tools suggests a more immediately usable solution within a hospital's imaging environment.
Clinical Value
TieBoth tools offer significant and distinct clinical value, being FDA-cleared for their respective applications. Imbio PHA provides automated, quantitative measurements from CTPA scans to aid in the diagnosis and risk stratification of pulmonary embolism and hypertension. KardiaAI offers AI-powered analysis of ambulatory ECGs for the detection of various cardiac arrhythmias like AFib, bradycardia, and tachycardia. Both address critical needs in cardiology with medical-grade accuracy.
Pricing & Value
KardiaAIKardiaAI offers transparent, subscription-based pricing with clear tiers (KardiaCare Monthly, Annual, Plus), allowing potential users to easily understand the cost and value proposition. Imbio PHA requires contacting the company for pricing, which is typical for enterprise medical imaging solutions but lacks the immediate transparency and direct comparison of value that KardiaAI provides.
Enterprise Readiness
Imbio PHA (4.0.0)Imbio PHA explicitly supports 'Enterprise (on-premise)' deployment options and integrates with native DICOM tools and workflows, which are crucial for large hospital systems and established healthcare IT infrastructures. Both tools are FDA-cleared and HIPAA compliant, but Imbio's specific mention of on-premise deployment and DICOM integration gives it an edge for traditional enterprise healthcare environments.
Innovation
TieBoth tools demonstrate significant innovation by applying AI to complex medical data. Imbio PHA innovates by automating precise anatomical measurements from 3D CT pulmonary angiogram scans for risk stratification in PE and hypertension. KardiaAI's innovation lies in its AI-powered library for real-time analysis of ambulatory ECG rhythms, making sophisticated arrhythmia detection widely accessible through API integration. They represent distinct yet equally impactful advancements in their respective domains.
Support & Docs
TieBoth Imbio and AliveCor (KardiaAI's company) provide comprehensive support channels, including phone and email, along with online resources and FAQs. Imbio offers 24/7/365 support and documentation upon request, while AliveCor provides extensive user manuals and troubleshooting guides for its Kardia products. Without specific metrics on the quality or responsiveness of their support, both appear to offer robust support and documentation.
Feature-by-Feature
Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.
| Feature | Imbio PHA (4.0.0) | KardiaAI |
|---|---|---|
| Tool Name | Imbio PHA (4.0.0) | KardiaAI |
| Company | Imbio | AliveCor |
| Primary Function/Input | AI-powered medical image processing software that automatically measures cardiac structures from CT pulmonary angiogram (CTPA) scans. | AI software library for analyzing ambulatory ECG rhythms. |
| Key Detections/Measurements | Automated measurement of right and left ventricle diameters; Automated measurement of main pulmonary artery and aorta diameters; Calculates RV/LV and PA/Ao ratios; Generates annotated DICOM images; Provides summary reports in PDF format. | Detection of atrial fibrillation, bradycardia, tachycardia, and normal sinus rhythm; Detection of Sinus Rhythm with Premature Ventricular Contractions (PVCs); Detection of Sinus Rhythm with Wide QRS; Detection of Sinus Rhythm with Supraventricular Ectopy (SVE); ECG noise filtering and noisy ECG detection. |
| Specialties | Cardiology, Pulmonology, Radiology | Cardiology, Emergency Medicine, Internal Medicine |
Videos
Demos, reviews, and walkthroughs featuring Imbio PHA (4.0.0) and KardiaAI.
Frequently Asked Questions
More Comparisons
More matchups featuring Imbio PHA (4.0.0) or KardiaAI
Backers
Who funded each tool's parent company.